LYCOS RETRIEVER 
Isis Pharmaceuticals
built 203 days ago
Isis Pharmaceuticals may not be all-powerful like its namesake, but the Goddess thinks it has a good thing going with its flagship product, Vitravene. Based on antisense technology, which inhibits cells from producing disease-causing proteins, the drug treats cytomegalovirus retinitis, a cause of blindness in AIDS patients. Partner Novartis Ophthalmics (a unit of druggernaut Novartis) sells the drug worldwide. Isis has other antisense-based drugs in various stages of development. Lead drug candidate Alicaforsen could help people suffering from ulcerative colitis, or inflammation of the colon. Other drug candidates target diabetes, elevated cholesterol levels, multiple sclerosis, and cancer.
Source:
Isis Pharmaceuticals: Isis Pharmaceuticals (ISIS: sentiment, chart, options) is on the rise today after announcing a collaborative effort with Johnson & Johnson's (JNJ) Ortho-McNeil unit. The 2 companies will work to research and develop treatments for metabolic diseases including Type 2 diabetes. ISIS will receive a $45 million upfront licensing fee from Ortho-McNeil. Additionally, ISIS could expect future sums of more than $230 million from various payments and royalties.
Source:
Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs. The Company has commercialized its first product, Vitravene® (fomivirsen), to treat CMV-induced retinitis in AIDS patients. In addition, Isis has 13 products in its development pipeline, with two in late-stage development and six in Phase II human clinical trials. LY900003 (ISIS 3521), an inhibitor of PKC-alpha, is in Phase III trials for non-small cell lung cancer, and alicaforsen (ISIS 2302), an ICAM-1 inhibitor, is in Phase III human clinical trials for Crohn's disease. Isis has a broad patent estate, as the owner or exclusive licensee of more than 900 issued patents worldwide. Isis' GeneTrove(TM) division uses antisense to assist pharmaceutical industry partners in validating and prioritizing potential gene targets through customized services.
Source:
Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs. The company has commercialized its first product, Vitravene(TM) (fomivirsen), to treat CMV-induced retinitis in AIDS patients. In addition, Isis has 11 products in its development pipeline, with two in late-stage development and four in Phase II human clinical trials. ISIS 3521, an inhibitor of PKC-alpha, is in Phase III trials for non-small cell lung cancer. Isis is preparing to initiate a Phase III program for ISIS 2302 (alicaforsen), an ICAM-1 inhibitor, in Crohn's disease. Isis has a broad patent estate, as the owner or exclusive licensee of over 780 issued patents worldwide.
Source:
ISIS 113715 is Isis Pharmaceuticals, Inc.'s second-generation antisense inhibitor of protein tyrosine phosphatase 1b (PTP-1b) for the treatment of type 2 diabetes. PTP-1b is responsible for turning off the activated insulin receptor, so by reducing levels of PTP-1b, ISIS 113715 enhances the activity of insulin. In June 2006, the Company announced Phase 2 results in patients with type 2 diabetes treated with ISIS 113715 as a single agent. The study was conducted in diagnosed type 2 diabetic patients with moderate diabetes and divided into two parts, a six week safety portion with ascending doses, and a three month portion at a weekly ISIS 113715 dose of 200 milligram /week designed to determine the effects of treatment with ISIS 113715 on several measures of blood glucose control.
Source:
Biotechnology company Genzyme said late Monday it agreed to develop and market Isis Pharmaceuticals' mipomersen. As part of the deal, Cambridge, Mass.-based Genzyme will make an initial payment of $325 million to Isis.
Source:
MORE ABOUT
Isis Pharmaceuticals